# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-054509
Filing Date
2026-02-17
Accepted
2026-02-17 15:57:28
Documents
81
Period of Report
2025-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | neup-20251231.htm iXBRL | 10-Q | 1818966
2 | EX-31.1 | neup-ex31_1.htm | EX-31.1 | 19952
3 | EX-31.2 | neup-ex31_2.htm | EX-31.2 | 20045
4 | EX-32.1 | neup-ex32_1.htm | EX-32.1 | 10964
5 | EX-32.2 | neup-ex32_2.htm | EX-32.2 | 12772
| Complete submission text file | 0001193125-26-054509.txt |  | 7353370

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | neup-20251231.xsd | EX-101.SCH | 999378
83 | EXTRACTED XBRL INSTANCE DOCUMENT | neup-20251231_htm.xml | XML | 1230777

Mailing Address 100 SUMMIT DR BURLINGTON MA 01803
Business Address 100 SUMMIT DR BURLINGTON MA 01803 781-439-5551
Neuphoria Therapeutics Inc. (Filer) CIK: 0001191070 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-41157 | Film No.: 26640520
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)